3 Key Takeaways
Plain English Summary- 01Core Finding
We screened pharmacological compounds for their ability to induce IL-10 expression in B cells.
- 02Study Evidence
Tested in a in vivo animal model (preclinical discovery) at the preclinical stage.
- 03Practical Meaning
Early laboratory or animal model findings — human trials are still needed to confirm safety and benefit.
What This Means for You
The therapeutic effect of IL-10 + B cell transfer was abrogated in mice lacking IL-10 receptor expression in long-lived myeloid cells, pointing to microglia as targets of B cell-derived IL-10. Importantly, an N6 analog corrected defective IL-10 expression in B cells from multiple sclerosis patients.
Our findings establish a pharmacological strategy to generate IL-10 + B cells with therapeutic potential and identify microglia as critical targets for intercepting neuroinflammatory disease progression.
The Discovery
The lack of approaches to produce interleukin (IL)-10-producing B cells at high frequency has hampered mechanistic investigation into the generation, fate, and activity of these regulatory cells. We screened pharmacological compounds for their ability to induce IL-10 expression in B cells. One compound, N6, promoted stable IL-10 expression in >95% of B cells. Transfer of IL-10 + B cells induced remission of experimental autoimmune encephalomyelitis. N6-induced B cells accumulated in the central nervous system (CNS) and differentiated into IL-10 + plasma cells, promoting transcriptional and phenotypic changes in myeloid cells within the CNS.
How It Works, Simply
This immunology research focuses on receptor targeting. Researchers evaluated it using an in vivo animal model (Preclinical discovery) at the preclinical stage of medical research.
3 Key Takeaways
Clinical Takeaways- 01Core Finding
We screened pharmacological compounds for their ability to induce IL-10 expression in B cells.
- 02Study Evidence
Tested in a in vivo animal model (preclinical discovery) at the preclinical stage.
- 03Practical Meaning
Early laboratory or animal model findings — human trials are still needed to confirm safety and benefit.
Biological Mechanism & Study Design
Study Design & Cohort
Animal models
In vivo animal model (Preclinical discovery) · Preclinical
Biological Pathway & Modality
Receptor targeting
Intervention: Induced regulatory B cells stably expressing interleukin-10 reverse central nervous
Experimental Findings & Endpoints
The lack of approaches to produce interleukin (IL)-10-producing B cells at high frequency has hampered mechanistic investigation into the generation, fate, and activity of these regulatory cells.
We screened pharmacological compounds for their ability to induce IL-10 expression in B cells. One compound, N6, promoted stable IL-10 expression in >95% of B cells.
Transfer of IL-10 + B cells induced remission of experimental autoimmune encephalomyelitis. N6-induced B cells accumulated in the central nervous system (CNS) and differentiated into IL-10 + plasma cells, promoting transcriptional and phenotypic changes in myeloid cells within the CNS.
Clinical Translation & Practice Context
The therapeutic effect of IL-10 + B cell transfer was abrogated in mice lacking IL-10 receptor expression in long-lived myeloid cells, pointing to microglia as targets of B cell-derived IL-10.
Importantly, an N6 analog corrected defective IL-10 expression in B cells from multiple sclerosis patients.
Our findings establish a pharmacological strategy to generate IL-10 + B cells with therapeutic potential and identify microglia as critical targets for intercepting neuroinflammatory disease progression.
The Bottom Line · Clinical Pearl
“Our findings establish a pharmacological strategy to generate IL-10 + B cells with therapeutic potential and identify microglia as critical targets for intercepting neuroinflammatory disease progression.”
Published in Immunity · Current Stage: Preclinical
